Immunology
Feature
As COVID treatments dwindle, are new ones waiting in the wings?
Bebtelovimab couldn’t neutralize the Omicron subvariants BQ.1 and BQ.1.1.
Feature
Have you heard of VEXAS syndrome?
The prevalence of this syndrome is unknown, but it is not so rare.
Feature
Have long COVID? Newest booster vaccines may help you
‘A bivalent booster might actually [help with] your long COVID,’ epidemiologist said.
News
FDA pulls U.S. authorization for Eli Lilly’s COVID drug bebtelovimab
The drug is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.
Feature
Buzzy Lancet long COVID paper under investigation for ‘data errors’
A reader found inconsistencies between the data in the article and a later paper describing the same cohort of patients after a year of follow-up...
Feature
Covid vax prevents death in children regardless of variant
But the vaccine’s effectiveness decreased over time.
Feature
More vaccinated people dying of COVID as fewer get booster shots
But the case for the effectiveness of vaccines and boosters versus skipping the shots remains strong.
From the Journals
Add tezepelumab to SCIT to improve cat allergy symptoms?
“Tezepelumab is currently an expensive biologic, so it remains to be seen whether patients and payors will be willing to pay for this add-on...
Feature
Doctors urge screening for autoimmune disorders for patients with celiac disease
At least in some cases, people with one autoimmune disorder should be tested for others, celiac disease specialists say.
Latest News
COVID bivalent booster better vs. recent Omicron subvariants: Pfizer
An ongoing phase 2 trail shows the vaccine offered the strongest protection in people older than 55 years.
From the Journals
Gene ‘cut-and-paste’ treatment could offer hope for inherited immune system diseases
“Collecting the T cells is easier and correcting the T cells is easier. With this approach the amount of time in hospital the patients would need...